Sanofi to Genzyme: Game On; Biotech Earnings, Trials Boost Stocks
July 30th 2010Genzyme's shares leaped after Sanofi's board authorized its chief executive to bid up to $70 per share for the drug maker, though Genzyme may hold out for as much as $75 per share. A slew of biotechs reported earnings, and upbeat clinical trial data boosted some stocks.